证券代码：688626 证券简称：翔宇医疗 公告编号：2023-043 二、提议人提议回购股份的原因和目的 河南翔宇医疗设备股份有限公司 关于公司实际控制人提议公司回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 河南翔宇医疗设备股份有限公司（以下简称"公司"）董事会于 2023 年 8 月 10 日收到公司实际控制人何永正、郭军玲夫妇递交的《关于提议河南翔 宇医疗设备股份有限公司回购公司股份的函》。何永正、郭军玲夫妇提议公司以 首发超募资金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发 行的部分人民币普通股（A 股）股票，具体内容如下： 一、提议人的基本情况及提议时间 1、提议人：公司实际控制人何永正、郭军玲夫妇 2、提议时间：2023 年 8 月 10 日 公司实际控制人何永正、郭军玲夫妇基于对公司未来发展的信心和对公司价 值的高度认可，为建立、完善公司长效激励机制，充分调动公司员工的积极性， 提高团队凝聚力和竞争力，有效地将股东利益、公司利益和员工利益紧密结合在 一起。经综合考 ...

上海市通力律师事务所 关于河南翔宇医疗设备股份有限公司 2023 年第一次临时股东大会的法律意见书 致:河南翔宇医疗设备股份有限公司 上海市通力律师事务所(以下简称"本所")接受河南翔宇医疗设备股份有限公司(以下 简称"公司")的委托,指派本所高云、杜颖律师(以下简称"本所律师")根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》等法律法规和规范性文 件(以下统称"法律法规")及《河南翔宇医疗设备股份有限公司章程》(以下简称"公司章 程")的规定就公司 2023 年第一次临时股东大会(以下简称"本次股东大会")相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 西走 HONG KONG 伦敦 LONDON 在此基础上,本所律师出具法律意见如下: 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 12 | | --- | --- | | 普通股股东人数 | 12 | | 2、出席会议的股东所持有的表决权数量 | 123,886,640 | | 普通股股东所持有表决权数量 | 123,886,640 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 78.6332 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 78.6332 | 证券代码：688626 证券简称：翔宇医疗 公告编号：2023-041 河南翔宇医疗设备股份有限公司 2023 年第一次临时股东大会决议公告 注：公司表决权数量不含截至股权登记日公司已回购股份的数量。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2023-042 河南翔宇医疗设备股份有限公司 关于 2023 年限制性股票激励计划内幕信息知情人 及激励对象买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 河南翔宇医疗设备股份有限公司（以下简称"公司"）于 2023 年 7 月 19 日召开第二届董事会第九次会议、第二届监事会第六次会议，审议通过了《关于 <公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》等议案，并于 2023 年 7 月 20 日在上海证券交易所网站（www.sse.com.cn）披露了相关公告。 根据《上市公司信息披露管理办法》、《上市公司股权激励管理办法》、《上 海证券交易所科创板股票上市规则》、《科创板上市公司自律监管指南第 4 号 ——股权激励信息披露》等法律、法规及规范性文件的要求，公司通过向中国证 券登记结算有限责任公司上海分公司对 2023 年限制性股票激励计划（以下简称 "本激励计划"）的内幕信息知情人及激励对象在本激励计划草案公开披露前 6 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a total revenue of 500 million RMB, representing a 20% year-over-year growth[1]. - The company achieved operating revenue of CNY 334.76 million in the first half of 2023, representing a 51.55% increase compared to the same period last year[21]. - Net profit attributable to shareholders reached CNY 107.61 million, up 169.00% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 94.77 million, an increase of 269.41%[23]. - The net cash flow from operating activities was CNY 100.55 million, a significant increase of 450.10% compared to the previous year[23]. - Basic earnings per share rose to CNY 0.68, reflecting a 172.00% increase from CNY 0.25 in the same period last year[22]. - The company achieved a revenue of 2,352.66 million, with a net profit of 164.99 million, marking a significant increase from the previous period[61]. - The company achieved a revenue of 2,432.43 million, with a year-on-year growth of 667.58 million, representing a 38% increase[64]. - The company reported a revenue of 37,589.55 million RMB in the first half of 2023, a significant increase from 29,457.40 million RMB in the same period last year, representing a growth of approximately 27.3%[69]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% compared to the first half[1]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 10%[1]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with potential targets identified[1]. - The company aims to improve its market position through strategic partnerships and potential acquisitions in the rehabilitation sector[15]. - The company plans to increase its market share by targeting both domestic and international markets for its rehabilitation solutions[15]. - The company is actively pursuing market expansion and product diversification to enhance its competitive edge in the rehabilitation and nursing sectors[62]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new technology development aimed at enhancing product efficiency[1]. - Research and development expenses accounted for 14.18% of operating revenue, a decrease of 5.53 percentage points compared to the previous year[22]. - The company has established a comprehensive R&D process that adheres to ISO13485 standards, ensuring risk control and feasibility throughout product development[44]. - The company has accumulated a significant number of proprietary core technologies over 20 years, with new applications introduced during the reporting period[50]. - The company has developed advanced technologies such as high-pressure pulse control and three-dimensional dynamic feedback analysis for its product lines[50][51]. - The company has developed over 30 specialized rehabilitation solutions, including pain rehabilitation, neurological rehabilitation, and postoperative rehabilitation solutions, addressing various clinical needs[80]. - The company has a strong focus on technology research and development, achieving modular and component-based construction to quickly meet clinical demands through integrated product development[81]. Product Development and Offerings - New product launches are expected to contribute an additional 100 million RMB in revenue by the end of the year[1]. - The company offers over 500 types of rehabilitation medical devices across 20 major series, providing a comprehensive product structure in the rehabilitation medical device field[39]. - The product line includes over 10 types of physical therapy technologies, such as shock wave therapy and biofeedback systems, aimed at improving patient outcomes[41]. - The company has developed a gait training system that incorporates intelligent control technology, enhancing rehabilitation for patients with various conditions[62]. - The company is enhancing its product offerings in postpartum rehabilitation, with a comprehensive product system for related therapies[66]. Operational Efficiency - The management highlighted a focus on improving operational efficiency, aiming for a 15% reduction in production costs by the end of the fiscal year[1]. - The company has established partnerships with three new distributors to enhance its distribution network, expected to boost sales by 20%[1]. - The company operates a complete system for product research and development, procurement, production, sales, and service in the rehabilitation medical industry[43]. - The company has a robust quality control capability and extensive production organization experience in the rehabilitation medical device sector[83]. Risk Management - Risk factors related to supply chain disruptions have been acknowledged, with mitigation strategies in place to minimize impact[1]. - The company faces risks related to technology innovation and competition in the rehabilitation equipment industry[96][97]. Corporate Governance and Compliance - The company has committed to transparency in related party transactions and will disclose necessary information in accordance with regulations[153]. - The company has established a commitment to ensure that any share reduction does not adversely affect its governance structure and ongoing operations[138]. - The company is focused on maintaining a strong corporate governance structure to support its IPO efforts[145]. Community Engagement and Environmental Responsibility - The company invested 187,500 RMB in environmental protection during the reporting period[125]. - The company provided 12,500 RMB in scholarships to 21 employees' children and one local impoverished college student, and donated 70,000 RMB for local road repairs[133].

Financial Performance - The company's operating revenue for 2022 was CNY 488.53 million, a decrease of 6.68% compared to CNY 523.50 million in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 12.55 million, down 37.85% from CNY 20.19 million in 2021[24]. - The basic earnings per share decreased by 41.48% to CNY 0.79 in 2022 from CNY 1.35 in 2021[24]. - The company's net profit attributable to the parent company was 125.47 million yuan, down 37.85% year-on-year, while the net profit after deducting non-recurring gains and losses was 77.79 million yuan, a decline of 48.76%[34]. - The company's total revenue for the year was CNY 483,871,268.14, representing a year-on-year decrease of 6.19%[150]. - The gross profit margin for the main business was 66.17%, a decrease of 2.01 percentage points compared to the previous year, primarily due to changes in the sales product structure[147]. Shareholder Returns - The proposed cash dividend for 2022 is CNY 2.40 per 10 shares, totaling CNY 37,812,000, which accounts for 30.14% of the net profit attributable to shareholders[5]. - The company repurchased shares amounting to CNY 73,270,345.21, representing 58.40% of the net profit attributable to shareholders for 2022[6]. - The total cash dividends distributed, including the repurchased shares, amount to CNY 111,082,345.21, which is 88.54% of the net profit attributable to shareholders for 2022[6]. Research and Development - The company's R&D expenses accounted for 18.92% of operating revenue, an increase of 5.81 percentage points compared to 13.11% in 2021[24]. - R&D expenses amounted to 92.41 million yuan, an increase of 34.70% year-on-year, accounting for 18.92% of total revenue, up 5.81 percentage points from the previous year[35]. - The total number of R&D personnel reached 434, accounting for 25.48% of the total workforce, with ongoing expansion of R&D centers in various cities[36]. - The company has obtained a total of 1,251 patents, with 402 patent applications submitted during the reporting period, including 81 invention patents[37]. - The company has developed advanced core technologies, including intelligent feedback systems for rehabilitation, which enhance patient safety and treatment effectiveness[92]. Market Position and Strategy - The company is positioned to address the growing demand for rehabilitation services, particularly for chronic and elderly patients[15]. - The rehabilitation medical device industry in China is expected to exceed 1 trillion yuan in main business revenue from 2021 to 2023[61]. - The average annual growth rate of the rehabilitation medical device industry is approximately 20%[64]. - The company aims to improve patient experience by reducing product delivery times through pre-production of high-demand components[57]. - The company is focusing on expanding its market presence through innovative product offerings and strategic partnerships in the rehabilitation sector[54]. Product Development and Innovation - The company launched a series of new rehabilitation products, including a comprehensive physical therapy system and a biofeedback-assisted electrical stimulation device, enhancing its product portfolio[44]. - The company has developed over 500 proprietary rehabilitation products across 20 categories, establishing a comprehensive product system in the rehabilitation medical device sector[51]. - The company has developed a comprehensive physical therapy system that integrates multiple treatment modalities to address common clinical conditions[53]. - The company is focusing on the development of traditional Chinese medicine rehabilitation equipment, which is expected to expand its market presence in hospitals and specialized clinics[180]. - The company is developing integrated solutions for over 30 clinical specialties, utilizing smart technology and ergonomic design to create a connected rehabilitation medical space[192]. Risk Management - The company has detailed risk factors in the management discussion and analysis section, advising investors to be cautious of investment risks[4]. - The company faces risks related to technological innovation and competition in the rapidly developing rehabilitation equipment industry[132]. - The company is exposed to industry policy changes, particularly in the rehabilitation medical device sector, which could impact pricing and bidding outcomes[139]. - The competitive landscape in the rehabilitation device market is intensifying, with potential risks to market share if growth does not meet expectations[140]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not experienced any inability of the majority of directors to ensure the authenticity and completeness of the annual report[8]. Awards and Recognition - The company was recognized as a "National Technology Innovation Demonstration Enterprise" and received the Henan Provincial Governor Quality Award in 2022[70]. - The company received multiple awards for its technological innovations, including first prize at the China Rehabilitation Medicine Association Science and Technology Award for three consecutive years[40]. - The company has been recognized as a national high-tech enterprise and a model production base for traditional Chinese medicine diagnostic equipment, reflecting its industry leadership[121].

河南翔宇医疗设备股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688626 证券简称：翔宇医疗 公告编号：2023-026 会议召开时间：2023 年 5 月 24 日（星期三）上午 9:00-10:00 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 17 日(星期三)至 5 月 23 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 xymedical@xyyl.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南翔宇医疗设备股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年年度报告、2023 年第一季度报告，为便于广大投资者更全面 深入地了解公司 20 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2023-025 河南翔宇医疗设备股份有限公司 关于参加河南辖区上市公司 2023 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，河南翔宇医疗设备股份有限公司定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景网举办的"真诚沟通 传递 价值"河南辖区上市公司 2023 年投资者网上集体接待日活动，本次活动将采用 网络远程的方式举行，投资者可登录"全景•路演天下"（http://rs.p5w.net） 参与本次互动交流。 出席本次网上集体接待日活动的人员有：董事、副总经理、董事会秘书郭军 玲女士，财务总监金宏峰先生（如有特殊情况，参会人员将可能进行调整），欢 迎广大投资者积极参与。 特此公告。 河南翔宇医疗设备股份有限公司董事会 2023 年 5 月 15 日 ...

Financial Performance - The company's operating revenue for Q1 2023 reached CNY 143,153,527.80, representing a year-on-year increase of 68.25%[4] - Net profit attributable to shareholders was CNY 37,812,580.60, marking a significant increase of 298.99% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was CNY 32,553,857.41, reflecting a substantial growth of 549.98% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.24, which is a 300% increase from the same period last year[4] - The net profit for Q1 2023 reached CNY 38,592,209.22, up from CNY 8,332,824.99 in Q1 2022, marking a growth of approximately 363.5%[21] - The earnings per share for Q1 2023 were CNY 0.24, compared to CNY 0.06 in Q1 2022, reflecting a 300% increase[22] Cash Flow - The net cash flow from operating activities amounted to CNY 36,450,103.71, an increase of 251.84% compared to the previous year[4] - In Q1 2023, the company generated operating cash inflow of CNY 183,353,703.59, a 72.7% increase from CNY 106,200,506.73 in Q1 2022[25] - The net cash flow from operating activities was CNY 36,450,103.71, compared to a negative cash flow of CNY -24,005,795.51 in the same period last year[25] - The company reported a total cash and cash equivalents balance of CNY 832,260,520.32 as of March 31, 2023, up from CNY 749,152,830.61 at the end of 2022[26] - Investment activities generated a net cash inflow of CNY 27,421,758.09, a significant improvement from a net outflow of CNY -52,946,795.92 in Q1 2022[26] - The company's cash inflow from sales of goods and services was CNY 162,957,664.29, up from CNY 94,386,927.88 in Q1 2022, representing a 72.9% increase[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,427,280,318.30, reflecting a 2.50% increase from the end of the previous year[5] - The total current assets decreased slightly to RMB 1,655,063,836.09 from RMB 1,668,379,570.59, indicating a decline of about 0.8%[17] - The company’s total liabilities increased, with short-term borrowings rising to CNY 58,000,000.00 from CNY 3,000,000.00 at the end of 2022[29] - The total liabilities for Q1 2023 were CNY 452,016,292.46, compared to CNY 428,219,732.64 in Q1 2022, which is an increase of approximately 5.5%[19] - The total assets as of Q1 2023 amounted to CNY 2,427,280,318.30, up from CNY 2,368,078,429.22 in the previous year, showing an increase of about 2.5%[19] Research and Development - Research and development expenses totaled CNY 21,608,723.98, accounting for 15.09% of operating revenue, a decrease of 6.54 percentage points year-on-year[5] - Research and development expenses for Q1 2023 were CNY 21,608,723.98, compared to CNY 18,405,732.79 in Q1 2022, indicating an increase of approximately 17.5%[21] - The company achieved 16 new medical device registrations and a total of 257 registrations, alongside 67 new patents, bringing the cumulative total to 1,318 patents[13] - The company reported a total of 83 new intellectual property rights in the current year, contributing to a cumulative total of 1,596 rights[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,994[9] - The total equity attributable to shareholders of the parent company was CNY 1,962,218,182.98, compared to CNY 1,927,592,482.34 in the previous year, showing an increase of approximately 1.8%[19] Inventory and Investments - The company’s inventory decreased to RMB 217,798,316.59 from RMB 222,820,180.68, reflecting a reduction of approximately 2.3%[17] - The company’s long-term equity investments decreased slightly to RMB 16,717,451.07 from RMB 17,086,737.70, a decline of about 2.2%[17] - The company’s fixed assets decreased to RMB 91,637,608.59 from RMB 93,870,801.11, a decline of about 2.4%[17] - The company’s construction in progress increased to RMB 385,358,997.23 from RMB 314,093,717.93, indicating a growth of approximately 22.7%[17] Recognition and Achievements - The company was recognized as a leading enterprise in intellectual property in Henan Province and approved as a model enterprise for industry-university-research cooperation in China[13]

Financial Performance - The company's operating revenue for 2022 was CNY 488.53 million, a decrease of 6.68% compared to CNY 523.50 million in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 125.47 million, down 37.85% from CNY 201.90 million in 2021[23]. - The basic earnings per share decreased by 41.48% to CNY 0.79 in 2022 from CNY 1.35 in 2021[24]. - The company's total revenue for the year was CNY 483,871,268.14, representing a year-on-year decrease of 6.19%[150]. - The net cash flow from operating activities for 2022 was CNY 186.70 million, an increase of 12.55% from CNY 165.88 million in 2021[23]. - The gross profit margin for the main business was 66.17%, a decrease of 2.01 percentage points compared to the previous year[147]. - The company reported a significant decrease in financing cash flow due to share repurchase activities, with a net outflow of 117.04 million yuan[147]. Shareholder Returns - The proposed cash dividend for 2022 is CNY 2.40 per 10 shares, totaling CNY 37,812,000, which accounts for 30.14% of the net profit attributable to shareholders[5]. - The company repurchased shares worth CNY 73,270,345.21, representing 58.40% of the net profit attributable to shareholders for 2022[6]. - Total cash dividends distributed, including share repurchases, amount to CNY 111,082,345.21, which is 88.54% of the net profit attributable to shareholders for 2022[6]. Research and Development - The company's R&D expenditure as a percentage of operating revenue increased by 5.81 percentage points to 18.92% in 2022, reflecting a commitment to technological innovation[24]. - R&D expenses amounted to 92.41 million yuan, an increase of 34.70% year-on-year, accounting for 18.92% of total revenue, up 5.81 percentage points from the previous year[35]. - The company has a total of 434 R&D personnel, accounting for 25.48% of the total workforce, with ongoing expansion of R&D centers in various cities[36]. - The company has obtained a total of 1,251 patents and participated in drafting or evaluating 29 national industry standards[122]. - The company is committed to continuous innovation and has established a comprehensive R&D system to support its product development and quality assurance[121]. Product Development and Innovation - The company launched a series of new rehabilitation products, including a comprehensive physical therapy system and a biofeedback-assisted electrical stimulation device, enhancing its product portfolio[44]. - The company has developed a VTE prevention information system to dynamically assess and recommend preventive measures for venous thromboembolism in hospitalized patients[53]. - The company has developed focused shock wave technology for precise treatment, enhancing rehabilitation solutions[77]. - The company has launched a pelvic floor functional magnetic stimulation device in 2022, expanding its product line in magnetic therapy[79]. - The company has developed a spinal decompression traction bed that has received registration certification, targeting treatment for cervical and lumbar diseases[112]. Market Position and Strategy - The company aims to enhance its competitive capabilities and solidify its industry position by focusing on quality, scale, and brand development in the rehabilitation medical device sector[71]. - The company is focusing on expanding its rehabilitation medical equipment market, with a target industry scale exceeding 700 billion by 2020[176]. - The company is actively investing in new product development and technology to meet the growing demand in the rehabilitation sector[176]. - The company aims to enhance its domestic market presence while actively expanding into international markets, focusing on differentiated and systematic rehabilitation solutions[186]. - The company is exploring strategic partnerships and market expansion opportunities to strengthen its position in the rehabilitation medical equipment industry[176]. Regulatory and Compliance - The company achieved ISO9001 and ISO13485 certifications, ensuring compliance with international quality management standards for medical devices[67]. - The company implemented a strict quality management system in compliance with ISO13485, ensuring product quality and safety throughout the production process[45]. - The company has been recognized as a "National Technology Innovation Demonstration Enterprise" and received the "Provincial Governor Quality Award" in 2022[70]. Industry Trends and Challenges - The rehabilitation medical device industry faces high technical and regulatory barriers, requiring companies to possess advanced technology and production capabilities[66]. - The competitive landscape in the rehabilitation device market is intensifying, with increased capital influx and market integration, posing a risk to market share if growth expectations are not met[140]. - The industry is moving towards more compact and portable devices to address space limitations in healthcare settings, facilitating easier transfer and precise functionality[88]. - The home healthcare market is expected to grow significantly due to aging populations and increased health awareness, presenting a substantial opportunity for rehabilitation devices[89]. Employee and Talent Development - The average salary of R&D personnel rose to 12.49 million RMB, compared to 10.87 million RMB in the previous year, indicating a focus on attracting and retaining talent[120]. - The company emphasizes talent development, focusing on training middle management and enhancing the skills of frontline employees to align with business growth[48]. - The company has resident after-sales engineers in all 31 provincial-level administrative regions, providing proactive after-sales service to enhance customer engagement[131].